KSKazuyuki Suzuki

Kazuyuki Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuyuki Suzuki has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 October 2014
      • Vol. 61  (135) , 2021-7

    Plasma from patients with acute liver failure dampens HepG2 cells to epidermal growth factor induced proliferation response.

    by Wei Li, Jun Long, Yasuhiro Takikawa, Kazuyuki Suzuki, Shide Lin

    The aims of this study are to explore the effects of epidermal growth factor (EGF) on hepatocyte proliferation in presence of plasma from patients with acute liver failure (ALF). HepG2 cells were cultured with 50% plasma from patients with ALF for 6, 12, 24, 48 and 72h with or without different concentrations of EGF. Cell proliferation was determined by the MTT assay and intracellular cyclin D1, cyclin-dependent kinase 4 (CDK4) expressions were analyzed by western blotting. The proliferation of HepG2 cells was significantly inhibited by treatment with plasma from patients with ALF from 12 to 72 h. Intracellular expression of cyclin D1 and CDK4 was also markedly down-regulated. 5ng/ml, 10ng/ml and 20ng/ml EGF dose dependently induced HepG2 proliferation in presence of plasma from normal control, but only 20ng/ml EGF showed a transient promoting effect on proliferation of HepG2 cells in presence of plasma from patients with ALF. Plasma from patients with ALF inhibits HepG2 cell proliferation via downregulation of cyclin D1 and CDK4 expression. Plasma from patient with ALF dampens HepG2 cells to EGF induced proliferation response.


  • Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma.

    by Kazuhiro Kasai, Kei Sawara, Kazuyuki Suzuki

    216 Background: Two recent phase III clinical trials have shown that sorafenib improves the survival in patients with advanced hepatocellular carcinoma (HCC). However, patients with HCC and portal vein tumor thrombosis (PVTT) usually have very short survival even when treated with sorafenib. On the other hand, recent advances in implantable drug delivery systems have made it possible to administer repeated hepatic arterial infusion chemotherapy (HAIC) agent. Since 2006, we have treated the patients displaying advanced HCC with PVTT by combined HAIC of 5-fluorouracil (5-FU) and systemic pegylated interferon (PEG-IFN)α-2b, and reported favorable results. In this article, we evaluated the efficacy of combined 5-FU and PEG-IFN α-2b, and compared outcomes between advanced HCC patients with PVTT treated using sorafenib. Methods: Forty patients with HCC and PVTT were enrolled. Of these, 21 patients were treated using subcutaneous administration of PEG-IFNα-2b and intra-arterial infusion of 5-FU [5-FU / PEG-IFN group], 19 patients were treated using continuous oral treatment with 400-800 mg of sorafenib [Sorafenib group]. We compared the early response to the therapy and the cumulative survival rate between these two groups. Results: The objective early response rate in the 5-FU / PEG-IFN group was significantly higher than that in the Sorafenib group (71.4 vs. 10.5%, P

  • Negative Regulation of Human Astrocytes by Interferon (IFN) α in Relation to Growth Inhibition and Impaired Glucose Utilization

    by Ting Wang, Yasuhiro Takikawa, Kei Sawara, Yuichi Yoshida, Kazuyuki Suzuki

    The present study assessed the direct effects of IFNs on human astrocytes. Human astrocytes were exposed to human recombinant IFNs, and the proliferation of cells was measured. Type I IFN receptor mRNA and protein expression, the phosphoprotein levels of signaling molecules including JNK, ERK1/2, IκB, p38MAPK, Stat3, and the expression of cytokines were determined respectively. In addition, cellular glucose consumption was measured as well as Glut-1 protein and activation of GSK-3β/mTOR signal were determined. The expression of Type I IFN receptor was detected in cultured human astrocytes. 2 IU/ml IFNα2a and IFNα2b significantly decreased the proliferation of human astrocytes respectively, compared to control. IFNβ had no significant effect on the proliferation of the cells. The phosphorylation of JNK stimulated by all IFNs detected was more pronounced and sustained than ERK1/2 and IκB. No effects were observed on the activation of p38MAPK and Stat3. Moreover, Treatment with IFNα, especially with IFNα2b, decreased glucose consumption and stimulated phosphorylation of GSK-3β and mTOR, but decreased the expression of Glut-1. In contrast, IFNβ had no significant effect on either glucose consumption or activation of GSK-3β/mTOR signals. INFα2b significantly decreased the levels of IL-8 whereas the levels of GM-CSF were increased. The present study demonstrates direct inhibitory effects of IFNα on cell proliferation, cell signaling and glucose utilization in human astrocytes.


    • 18 March 2011
      • Vol. 57, 1203-7

    Non-invasive evaluation of liver fibrosis using acoustic radiation force impulse imaging in chronic hepatitis patients with hepatitis C virus infection.

    by Hidekatsu Kuroda, Keisuke Kakisaka, Yoshinori Tatemichi, Kei Sawara, Yasuhiro Miyamoto, Kanta Oikawa, Akio Miyasaka, Yasuhiro Takikawa, Tomoyuki Masuda, Kazuyuki Suzuki

    Acoustic radiation force impulse (ARFI) imaging is a new technology for performing liver elastography. However, use of this technique to estimate the degree of fibrosis in chronic liver disease (CLD) related to hepatitis C virus (HCV) infection has not yet been established. We evaluated the validity, accuracy and flexibility of the ARFI method in CLD. Subjects comprised 30 patients with chronic hepatitis (CH), 30 patients with liver cirrhosis (LC) and 10 healthy subjects (controls). All patients had HCV infection. Elastography of the liver was performed at different sites using the ARFI method. Relationships between shear wave velocity (SWV) obtained by ARFI, clinical diagnosis, serum parameters of liver function and fibrosis in the liver were evaluated. Moreover, cut-off values for differential diagnosis between CH and LC were estimated using area under the receiver operating characteristics (AUROC). Mean SWV (+/- standard deviation) was 2.67 +/- 1.18 m/s, 1.33 +/- 0.54 m/s and 0.99 +/- 0.21 m/s in the LC, CH and control groups, respectively. SWV was significantly higher in the LC group than in the CH and control groups (p < 0.0001), and in the CH group than in the control group (p = 0.0023). SWV in each stage of fibrosis was 1.09 +/- 0.22 m/s in F0-1, 1.24 +/- 0.52 m/s in F2, 1.61 +/- 0.79 m/s in F3, and 2.35 +/- 1.11 m/s in F4. SWV correlated significantly with serum total bilirubin, alanine aminotransferase, cholesterol, albumin, platelet counts, prothrombin time, fibrosis markers, hyaluronic acid and type IV collagen. A steady stepwise increase in elasticity correlated significantly with severity of hepatic fibrosis (p = 0.9772; p = 0.002). Diagnostic ability for LC was superior in ARFI (AUROC, 0.930 in ARFI; 0.846 in aspartate aminotransferase to platelet ratio index; 0.829 in Forns' index; and 0.785 in platelet count). ARFI is extremely useful for distinguishing between CH and LC, and SWV might correlate significantly with degree of progression in CLD with HCV infection.


    • 1 January 2011
      • Vol. 108  (1) , 95-102

    A case of hepatocellular carcinoma with bleeding gingival metastasis treated by transcatheter arterial embolization.

    by Hirotsugu Inaba, Noriyoshi Kanazawa, Isao Wada, Kazuo Yoneyama, Tomoo Fujii, Takao Hoshino, Hiroyuki Watanabe, Masayo Komatsu, Yuko Fujishima, Yasuhiro Takikawa, et al.

    The patient was a terminally ill 80-year-old man with multiple lung metastases from hepatocellular carcinoma, that had developed following hepatitis-C virus-associated cirrhosis. He was admitted to our hospital with gingival bleeding, and we diagnosed gingival metastasis from hepatocellular carcinoma, based on histological examination. The bleeding could not be controlled, and the patient became dyspneic. After transcatheter arterial embolization, his bleeding was successfully controlled until his death due to respiratory failure. Transcatheter arterial embolization was a safe and effective treatment in our case.


  • Open Access

    Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype

    by Tamotsu Sugai, Mitsunori Tsukahara, Masaki Endoh, Yoshihiro Shioi, Noriko Takebe, Yoshiharu Mue, Hiroo Matsushita, Minoru Toyota, Kazuyuki Suzuki

    Abnormalities of cell cycle regulators are common features in human cancers, and several of these factors are associated with the early development of gastric cancers. However, recent studies have shown that gastric cancer tumorigenesis was characterized by mucin expression. Thus, expression patterns of cell cycle-related proteins were investigated in the early phase of differentiated-type gastric cancers to ascertain any mechanistic relationships with mucin phenotypes. Immunostaining for Cyclins D1, A, E, and p21, p27, p53 and β-catenin was used to examine impairments of the cell cycle in 190 gastric intramucosal differentiated-type cancers. Mucin phenotypes were determined by the expressions of MUC5AC, MUC6, MUC2 and CD10. A Ki-67 positive rate (PR) was also examined. Overexpressions of p53, cyclin D1 and cyclin A were significantly more frequent in a gastric phenotype than an intestinal phenotype. Cyclin A was overexpressed in a mixed phenotype compared with an intestinal phenotype, while p27 overexpression was more frequent in an intestinal phenotype than in a mixed phenotype. Reduction of p21 was a common feature of the gastric intramucosal differentiated-type cancers examined. Our results suggest that the levels of some cell cycle regulators appear to be associated with mucin phenotypes of early gastric differentiated-type cancers.


    • 1 January 2010
      • Vol. 107  (1) , 14-21

    [Current management for hepatic encephalopathy in cirrhotic patients].

    by Kazuyuki Suzuki